TY - JOUR
T1 - Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission
AU - Sproat, Lisa
AU - Bolwell, Brian
AU - Rybicki, Lisa
AU - Tench, Shawnda
AU - Chan, Josephine
AU - Kalaycio, Matt
AU - Dean, Robert
AU - Sobecks, Ronald
AU - Pohlman, Brad
AU - Andresen, Steven
AU - Sweetenham, John
AU - Copelan, Edward
PY - 2010/9
Y1 - 2010/9
N2 - Patients with acute myeloid leukemia (AML) with intermediate or high risk cytogenetics are often considered for allogeneic hematopoietic stem cell transplant (AHSCT) in first remission. Between attainment of remission and AHSCT, post-remission chemotherapy is frequently administered, though there is no evidence for its effectiveness. This study was performed to determine the impact of post-remission chemotherapy on outcome after AHSCT. A subset analysis was performed to determine whether the influence of post-remission chemotherapy might be different in those with intermediate compared to high risk cytogenetics. There was no significant difference in relapse mortality (RM) (p = 0.70), non-relapse mortality (NRM) (p = 0.12), or survival (OS) (p = 0.15) between post-remission chemotherapy groups. There was no difference in RM, NRM, or OS between cytogenetic groups according to whether they received post-remission chemotherapy. No differential effect between intermediate and high risk cytogenetics was detected (RM, p = 0.80; NRM, p = 0.23; OS, p = 0.26). These data do not show a benefit of post-remission chemotherapy before AHSCT.
AB - Patients with acute myeloid leukemia (AML) with intermediate or high risk cytogenetics are often considered for allogeneic hematopoietic stem cell transplant (AHSCT) in first remission. Between attainment of remission and AHSCT, post-remission chemotherapy is frequently administered, though there is no evidence for its effectiveness. This study was performed to determine the impact of post-remission chemotherapy on outcome after AHSCT. A subset analysis was performed to determine whether the influence of post-remission chemotherapy might be different in those with intermediate compared to high risk cytogenetics. There was no significant difference in relapse mortality (RM) (p = 0.70), non-relapse mortality (NRM) (p = 0.12), or survival (OS) (p = 0.15) between post-remission chemotherapy groups. There was no difference in RM, NRM, or OS between cytogenetic groups according to whether they received post-remission chemotherapy. No differential effect between intermediate and high risk cytogenetics was detected (RM, p = 0.80; NRM, p = 0.23; OS, p = 0.26). These data do not show a benefit of post-remission chemotherapy before AHSCT.
KW - Acute myeloid leukemia
KW - hematopoietic stem cell transplant
KW - post-remission consolidation
UR - http://www.scopus.com/inward/record.url?scp=77956324597&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956324597&partnerID=8YFLogxK
U2 - 10.3109/10428194.2010.500431
DO - 10.3109/10428194.2010.500431
M3 - Article
C2 - 20629524
AN - SCOPUS:77956324597
SN - 1042-8194
VL - 51
SP - 1
EP - 6
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 9
ER -